Ignite Creation Date:
2024-05-06 @ 7:40 PM
Last Modification Date:
2024-10-26 @ 3:11 PM
Study NCT ID:
NCT06094530
Status:
RECRUITING
Last Update Posted:
2023-10-23
First Post:
2023-10-16
Brief Title:
18F-FAPI-RGD PETCT in Various Tumor Types
Sponsor:
Sichuan Provincial Peoples Hospital
Organization:
Sichuan Provincial Peoples Hospital
Study Overview
Official Title:
Clinical Evaluation of 18F-FAPI-RGD PETCT for Imaging of Fibroblast Activation Protein and Integrin avb3 in Various Tumor Types
Status:
RECRUITING
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The clinical feasibility of 18F-FAPI-RGD PETCT will be evaluated in 100 patients with various types of tumor and the results will be compared with those of 18F-FDG
Detailed Description:
The aim of this study is to evaluate in patients with various types of tumor the radiotracer uptake and clinical feasibility of 18F-FAPI-RGD PETCT compared with those of 18F-FDG PETCT To evaluate the diagnostic performance of 18F-FAPI-RGD and 18F-FDG PET imaging the results of the visually interpreted PET images will be compared with the histopathologic results via surgery or biopsy which are used as the gold standard for the final diagnosis For patients for whom tissue diagnosis is not applicable clinical and radiographic follow-up data will be used as the reference standard to validate the PETCT findings
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None